Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00153140 · ClinicalTrials.gov registry record · Phase 4

Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation

A Phase 4 study, sponsored by Braintree Laboratories.

Completed
Registry status
Phase 4
Development phase
239
Enrollment target

NCT00153140 is a Phase 4 study that has completed, run by Braintree Laboratories. The registered enrollment target is 239 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00153140, a Phase 4 study, has completed, sponsored by Braintree Laboratories.

COMPLETED
Registry status
Phase 4
Development phase
239 participants
Enrollment target

Study Summary

The purpose of this study is to compare the safety and efficacy of extended polyethyleneglycol3350 use to tegaserod in patients with chronic constipation.

Interventions

  • DRUG polyethyleneglycol3350

Trial Details

FieldValue
Enrollment Target 239 participants
Start Date 2004-07
Phase Phase 4

Sponsor

Braintree Laboratories

49 total trials

What the Registry Record Tells You About NCT00153140

The ClinicalTrials.gov registry entry for NCT00153140 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 239 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Braintree Laboratories, which has 49 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which polyethyleneglycol3350 is the first listed.

NCT00153140 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00153140 about?

NCT00153140 is a clinical study titled "Polyethyleneglycol3350 vs Tegaserod in Treatment of Patients With Chronic Constipation". The purpose of this study is to compare the safety and efficacy of extended polyethyleneglycol3350 use to tegaserod in patients with chronic constipation.

What is the current status of trial NCT00153140?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 239 participants. The study started on 2004-07.

What interventions are being tested in trial NCT00153140?

The interventions under investigation include: polyethyleneglycol3350 (DRUG).

Who is sponsoring clinical trial NCT00153140?

This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.